In this assay, neutralizing antibodies in the sera of COVID-19 patients compete with human ACE2 protein standard for binding to SARS-CoV-2 RBD antigens (Wuhan, alpha, beta and gamma strains) immobilized on the plate surface. This evidence concerns the gene ACE2 and COVID-19.